Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
about
Anti-human SIRPα antibody is a new tool for cancer immunotherapy.Complement C3 Produced by Macrophages Promotes Renal Fibrosis via IL-17A SecretionAttenuation of CD47-SIRPα Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic MetastasisALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
P2860
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
@en
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
@nl
type
label
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
@en
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
@nl
prefLabel
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
@en
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
@nl
P2093
P2860
P356
P1476
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
@en
P2093
Aaron M Ring
Aaron McCarty
Benson M George
Irving L Weissman
Jens-Peter Volkmer
Kelly M McKenna
Kipp Weiskopf
Liang Shan
Melanie Lietzenmayer
Nan Guo Ring
P2860
P304
E10578-E10585
P356
10.1073/PNAS.1710877114
P407
P577
2017-11-20T00:00:00Z